Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05368935 · ClinicalTrials.gov registry record · Phase 1

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

A Phase 1 study, sponsored by Genfit.

Completed
Registry status
Phase 1
Development phase
77
Enrollment target

NCT05368935 is a Phase 1 study that has completed, run by Genfit. The registered enrollment target is 77 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05368935, a Phase 1 study, has completed, sponsored by Genfit.

COMPLETED
Registry status
Phase 1
Development phase
77 participants
Enrollment target

Study Summary

This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with renal impairment and healthy adults.

Interventions

  • DRUG Nitazoxanide

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2022-04-25
Est. Completion 2022-09-09
Phase Phase 1

Sponsor

Genfit

11 total trials

What the Registry Record Tells You About NCT05368935

The ClinicalTrials.gov registry entry for NCT05368935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genfit, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nitazoxanide is the first listed.

NCT05368935 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05368935 about?

NCT05368935 is a clinical study titled "Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects". This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with renal impairment and healthy adults.

What is the current status of trial NCT05368935?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2022-04-25. Estimated completion is 2022-09-09.

What interventions are being tested in trial NCT05368935?

The interventions under investigation include: Nitazoxanide (DRUG).

Who is sponsoring clinical trial NCT05368935?

This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.